Krapez Uros, Kuhar Urska, Šenica Petra, Slavec Brigita, Cosic Drasko, Loncarevic Ivan, Janezic Sandra, Cosic Irena
Institute for Poultry, Birds, Small Mammals, and Reptiles, Veterinary Faculty, University of Ljubljana, Ljubljana, Slovenia.
Institute of Microbiology and Parasitology, Veterinary Faculty, University of Ljubljana, Ljubljana, Slovenia.
PLoS One. 2025 Jul 22;20(7):e0327582. doi: 10.1371/journal.pone.0327582. eCollection 2025.
The SARS-CoV-2 virus has mutated over time, resulting in variations of circulating viral variants, which may impact the virus's properties, such as transmission or the severity of symptoms. Thus, there is a need for comprehensive approach less dependent of viral variants. For that purpose, we have employed the innovative and unique Resonant Recognition Model (RRM) to identify the common characteristics of all variants of SARS-CoV-2 virus and based on these characteristics, we have explored the possibility to develop approach against SARS-CoV-2 infection, less dependent on viral variants. This paper is a continuation of our previous research, where we have used the RRM model to design de novo peptide CovA, capable to prevent SARS-CoV-2 interaction with ACE2 receptor on host cells. Using Inhibitor Screening Assay Kits and viral replication in SARS-CoV-2/Vero E6 cells model, it has been previously shown that CovA can prevent viral interaction with receptor and viral replication in host cells. This test has been done on Wuhan variant only. Here, we have tested this RRM designed peptide CovA for efficiency with some other different SARS-CoV-2 variants. It has been shown here, that CovA act on all tested viral variants, but with different efficiency. Apart from representing the basis of new COVID-19 drugs discovery, this research once again presents the ability of RRM model to design de novo bioactive peptides with desired biological function.
严重急性呼吸综合征冠状病毒2（SARS-CoV-2）病毒随时间发生了变异，导致循环病毒变体出现变化，这可能会影响病毒的特性，如传播或症状的严重程度。因此，需要一种较少依赖病毒变体的综合方法。为此，我们采用了创新且独特的共振识别模型（RRM）来识别SARS-CoV-2病毒所有变体的共同特征，并基于这些特征，探索开发一种针对SARS-CoV-2感染的方法的可能性，该方法较少依赖病毒变体。本文是我们之前研究的延续，在之前的研究中，我们使用RRM模型从头设计了肽CovA，它能够阻止SARS-CoV-2与宿主细胞上的血管紧张素转换酶2（ACE2）受体相互作用。使用抑制剂筛选检测试剂盒以及在SARS-CoV-2/非洲绿猴肾细胞（Vero E6）模型中的病毒复制，之前已经表明CovA可以阻止病毒与受体的相互作用以及在宿主细胞中的病毒复制。该测试仅在武汉变体上进行。在此，我们用一些其他不同的SARS-CoV-2变体测试了这种由RRM设计的肽CovA的有效性。结果表明，CovA对所有测试的病毒变体都有作用，但效率不同。除了为新型冠状病毒肺炎（COVID-19）药物研发奠定基础外，这项研究再次展示了RRM模型设计具有所需生物学功能的从头生物活性肽的能力。
